Management Team

Combining oncology drug development and biomarker technology experience to improve cancer care

Vicki Kelemen

Chief Operating Officer

Vicki Kelemen has served as Chief Operating Officer since 2020, and previously as Vice President of Clinical Development and Investor Relations since 2018, and Vice President of Corporate Communications from 2017 to 2018 and Senior Director of Marketing Communications from 2015 to 2017.

Prior to joining Cardiff Oncology (formerly Trovagene), Ms. Kelemen was Sr. Vice President at a global healthcare communications agency, where she specialized in the market development and commercialization of therapeutics for serious and rare diseases, as well as the development of patient advocacy programs. Previously, Ms. Kelemen held progressive operations, marketing and communications management and executive positions and lead the development and launch of several novel products with pharma/biotech companies focused in therapeutics, including Amylin, Maxim, Agouron (Pfizer), Valeant, Ardea Biosciences (Astra Zeneca) and Dura Pharmaceuticals. Ms. Kelemen began her career in healthcare with Bayer Pharmaceuticals, where she held positions is sales, sales training, and marketing.

Ms. Kelemen has a BS degree in pre-med and medical anthropology from the University of California at Davis.